New MRI techniques aim to spy on brain Tumor's immune defenses

NCT ID NCT07461948

Recruiting now Knowledge-focused Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests three advanced MRI methods to non-invasively look at the immune cells and proteins around glioblastoma tumors. Researchers will compare MRI results with tissue samples from 15 patients scheduled for surgery. The goal is to see if these scans can replace biopsies for understanding why some tumors are harder to treat.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ferumoxytol (contrast agent)
What this could lead to: If successful, this could lead to a non-invasive way to understand why some glioblastomas resist treatment, potentially guiding future therapies.
What could go wrong: This is a small, early-phase study focused on imaging, not treatment. The techniques may not reliably reflect the immune environment, and results may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.